2. Gene
  3. Dars - aspartyl-tRNA synthetase Gene

Dars - aspartyl-tRNA synthetase Gene

  • Gene
  • Protein
  • Agent
Mus musculus

Also known as Dars1; 5730439G15Rik

Gene ID: 226414 | Gene type: protein coding

About Dars

Summary

Predicted to enable RNA binding activity and aspartate-tRNA Ligase activity. Predicted to be involved in aspartyl-tRNA aminoacylation. Predicted to act upstream of or within translation. Located in cytoplasm and synapse. Part of Aminoacyl-tRNA Synthetase multienzyme complex. Is expressed in several structures, including alimentary system; brain; genitourinary system; respiratory system; and sensory organ. Orthologous to human DARS1 (aspartyl-tRNA synthetase 1). [provided by Alliance of Genome Resources, Apr 2022]

Dars Products(2)

mRNA Protein Name
NM_145507.2 NP_663482.2 aspartate--tRNA ligase, cytoplasmic isoform 2
NM_177445.5 NP_803228.2 aspartate--tRNA ligase, cytoplasmic isoform 1
Gene Ontology
  • Cellular Component
Cellular Component GO Annotation Evidence Reference Source
part of aminoacyl-tRNA synthetase multienzyme complex IDA
IDA: Inferred from direct assay
12060739 MGI
located in cytoplasm IDA
IDA: Inferred from direct assay
27816769 MGI
located in synapse IDA
IDA: Inferred from direct assay
27816769 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

aspartate--tRNA ligase, cytoplasmic

aspRS

aspartyl-tRNA synthetase, cytoplasmic

Related Agents

Approval
Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10122 Silodosin Antagonist 99.82% Yes
Clinical Phase
Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-101299B Dihydrexidine hydrochloride Agonist 98.89% Phase 1
HY-101299A Dihydrexidine Agonist / Phase 1
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P99542 Tusamitamab ravtansine Inhibitor 99.42% Phase 3
HY-P99829 Cofetuzumab pelidotin Inhibitor 99.67% Phase 1
Pre-clinical Phase
Bioactive Molecules (20)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-145448 MC-VC-PABC-amide-PEG1-CH2-CC-885 99.93% Unkown
HY-164152A ADC Control Human IgG1-Deruxtecan (DAR 8) Inhibitor 97.75% Unkown
HY-100554 BMY 7378 99.92% Unkown
HY-101300 Cirazoline hydrochloride Agonist 99.65% Unkown
HY-101299 (+)-Dihydrexidine hydrochloride Agonist / Unkown
HY-RS03532 DARS1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS03533 DARS2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-116982 BMY 7378 free base / Unkown
HY-118260 Phendioxan / Unkown
HY-136884 DAR-4M / Unkown
HY-148252 ADRA1D receptor antagonist 1 free base Antagonist / Unkown
HY-156299 NMS-P945 / Unkown
HY-161901 BC-1293 Inhibitor / Unkown
HY-175504 MLS6357 Antagonist / Unkown
HY-175669 ANO1-IN-5 Inhibitor / Unkown
HY-10122S Silodosin-d4 Antagonist / Unkown
HY-RS20900 Dars1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS21545 Dars2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS27417 Dars1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS28063 Dars2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-164152 ADC Control Human IgG1-Deruxtecan (DAR 4) Inhibitor 97.40% Unkown
HY-141599 Camidanlumab tesirine Inhibitor / Unkown